KNP-301

N/A

Report date: 2024/02/04 13:28:12

Base Information

Drug NameKNP-301
Drug Alias NameKNP-301
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment
Mechanisms of ActionVascular endothelial growth factor bindersComplement C3b inactivator proteins inhibitors
TargetsVascular endothelial growth factorComplement C3b inactivator proteins
Therapy Area/IndicationsDiabetic macular oedemaWet age-related macular degenerationGeographic Atrophy +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesKanaph Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesKanaph Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsDiabetic macular oedemaWet age-related macular degenerationGeographic Atrophy +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A